therapeut
yet
proven
effect
treatment
sever
ill
caus
conduct
random
control
openlabel
trial
involv
hospit
adult
patient
confirm
infect
caus
respiratori
ill
oxygen
satur
sao
less
breath
ambient
air
ratio
partial
pressur
oxygen
pao
fraction
inspir
oxygen
fio
less
mm
hg
patient
randomli
assign
ratio
receiv
either
lopinavirritonavir
mg
mg
respect
twice
day
day
addit
standard
care
standard
care
alon
primari
end
point
time
clinic
improv
defin
time
random
either
improv
two
point
sevencategori
ordin
scale
discharg
hospit
whichev
came
first
total
patient
laboratoryconfirm
infect
underw
random
assign
lopinavirritonavir
group
standardcar
group
treatment
lopinavirritonavir
associ
differ
standard
care
time
clinic
improv
hazard
ratio
clinic
improv
confid
interv
ci
mortal
day
similar
lopinavirritonavir
group
standardcar
group
vs
differ
percentag
point
ci
percentag
patient
detect
viral
rna
variou
time
point
similar
modifi
intentiontotreat
analysi
lopinavirritonavir
led
median
time
clinic
improv
shorter
day
observ
standard
care
hazard
ratio
ci
gastrointestin
advers
event
common
lopinavirritonavir
group
seriou
advers
event
common
standardcar
group
lopinavirritonavir
treatment
stop
earli
patient
advers
event
conclus
h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
b
egin
decemb
novel
coronaviru
design
caus
intern
outbreak
respiratori
ill
term
full
spectrum
rang
mild
selflimit
respiratori
tract
ill
sever
progress
pneumonia
multiorgan
failur
death
thu
far
specif
therapeut
agent
coronaviru
infect
emerg
sever
acut
respiratori
syndrom
sar
screen
approv
drug
identifi
lopinavir
human
immunodefici
viru
hiv
type
aspart
proteas
inhibitor
vitro
inhibitori
activ
sarscov
viru
caus
sar
human
ritonavir
combin
lopinavir
increas
plasma
halflif
inhibit
cytochrom
openlabel
studi
publish
suggest
comparison
histor
control
group
receiv
ribavirin
addit
lopinavirritonavir
mg
mg
respect
ribavirin
reduc
risk
advers
clinic
outcom
acut
respiratori
distress
syndrom
ard
death
well
viral
load
among
patient
sar
howev
lack
random
contemporari
control
group
concomit
use
glucocorticoid
ribavirin
studi
made
effect
lopinavirritonavir
difficult
assess
similarli
lopinavir
activ
vitro
anim
model
middl
east
respiratori
syndrom
coronaviru
merscov
case
report
suggest
combin
lopinavirritonavir
ribavirin
interferon
alfa
result
virolog
clearanc
surviv
howev
convinc
data
efficaci
approach
human
lack
clinic
trial
recombin
interferon
mer
current
way
clinicaltrialsgov
number
evalu
efficaci
safeti
oral
lopinavirritonavir
infect
conduct
random
control
openlabel
trial
lotu
china
lopinavir
trial
suppress
china
adult
patient
hospit
patient
assess
elig
basi
posit
reversetranscriptasepolymerasechainreact
rtpcr
assay
shanghai
zj
biotec
sansur
biotech
respiratori
tract
sampl
test
local
center
diseas
control
cdc
design
diagnost
laboratori
male
nonpregn
femal
patient
year
age
older
elig
diagnost
specimen
posit
rtpcr
pneumonia
confirm
chest
imag
oxygen
satur
sao
less
breath
ambient
air
ratio
partial
pressur
oxygen
pao
fraction
inspir
oxygen
fio
pao
fio
mg
hg
exclus
criteria
includ
physician
decis
involv
trial
patient
best
interest
presenc
condit
would
allow
protocol
follow
safe
known
allergi
hypersensit
lopinavirritonavir
known
sever
liver
diseas
eg
cirrhosi
alanin
aminotransferas
level
upper
limit
normal
rang
aspart
aminotransferas
level
upper
limit
normal
rang
use
medic
contraind
lopinavirritonavir
could
replac
stop
trial
period
see
supplementari
appendix
avail
full
text
articl
nejmorg
pregnanc
breastfeed
known
hiv
infect
concern
develop
resist
lopinavirritonavir
use
without
combin
antiretrovir
patient
unabl
swallow
receiv
lopinavirritonavir
nasogastr
tube
openlabel
individu
random
control
trial
conduct
januari
februari
date
enrol
last
patient
jin
yintan
hospit
wuhan
hubei
provinc
china
emerg
natur
trial
placebo
lopinavirritonavir
prepar
elig
patient
randomli
assign
ratio
receiv
either
lopinavirritonavir
mg
mg
oral
freeli
provid
nation
health
author
twice
daili
plu
standard
care
standard
care
alon
day
standard
care
compris
necessari
supplement
oxygen
noninvas
invas
ventil
antibiot
agent
vasopressor
support
renalreplac
therapi
extracorpor
membran
oxygen
ecmo
balanc
distribut
oxygen
support
two
group
indic
sever
respiratori
failur
random
stratifi
basi
respiratori
support
method
time
enrol
oxygen
support
oxygen
support
nasal
duct
mask
highflow
oxygen
noninvas
ventil
invas
ventil
includ
ecmo
permut
block
four
patient
per
block
random
sequenc
includ
stratif
prepar
statistician
involv
trial
use
sa
softwar
version
sa
institut
minim
alloc
bia
perform
alloc
conceal
interact
webbas
respons
system
random
finish
system
comput
phone
trial
approv
institut
review
board
jin
yintan
hospit
written
inform
consent
obtain
patient
patient
legal
repres
patient
unwel
provid
consent
trial
conduct
accord
principl
declar
helsinki
good
clinic
practic
guidelin
intern
confer
harmonis
author
respons
design
trial
compil
analyz
data
author
vouch
complet
accuraci
data
adher
trial
protocol
full
detail
trial
design
provid
protocol
avail
nejmorg
patient
assess
daili
train
nurs
use
diari
card
captur
data
sevencategori
ordin
scale
safeti
day
day
hospit
discharg
death
safeti
monitor
good
clinic
practic
offic
jin
yintan
hospit
clinic
data
record
use
whoisar
world
health
organizationintern
sever
acut
respiratori
emerg
infect
consortium
case
record
form
http
isar
tghn
org
serial
oropharyng
swab
sampl
obtain
day
lopinavirritonavir
administ
day
discharg
death
occur
test
teddi
clinic
research
laboratori
tigermeddian
joint
ventur
use
quantit
realtim
rtpcr
see
supplementari
appendix
rna
extract
clinic
sampl
magna
pure
system
detect
quantifi
coba
qpcr
roch
use
lightmix
modular
assay
tib
mobiol
sampl
obtain
patient
still
aliv
everi
time
point
sampl
stop
swab
given
time
point
neg
baselin
throat
swab
test
detect
e
gene
rdrp
gene
n
gene
sampl
subsequ
visit
quantit
qualit
detect
e
gene
clinic
data
record
paper
case
record
form
doubleent
electron
databas
valid
trial
staff
primari
end
point
time
clinic
improv
defin
time
random
improv
two
point
statu
random
sevencategori
ordin
scale
live
discharg
hospit
whichev
came
first
end
point
clinic
improv
use
previou
influenza
studi
also
recommend
r
blueprint
expert
group
ordin
scale
use
end
point
clinic
trial
patient
hospit
sever
influenza
sevencategori
ordin
scale
consist
follow
categori
hospit
resumpt
normal
activ
hospit
unabl
resum
normal
activ
hospit
requir
supplement
oxygen
hospit
requir
supplement
oxygen
hospit
requir
nasal
highflow
oxygen
therapi
noninvas
mechan
ventil
hospit
requir
ecmo
invas
mechan
ventil
death
clinic
outcom
includ
clinic
statu
assess
sevencategori
ordin
scale
day
mortal
day
durat
mechan
ventil
durat
hospit
survivor
time
day
treatment
initi
death
virolog
measur
includ
proport
viral
rna
detect
time
viral
rna
titer
areaunderthecurv
auc
measur
safeti
outcom
includ
advers
event
occur
treatment
seriou
advers
event
prematur
discontinu
treatment
advers
event
classifi
accord
nation
cancer
institut
common
terminolog
criteria
advers
event
version
trial
initi
rapid
respons
public
health
emerg
time
h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
limit
inform
clinic
outcom
hospit
patient
origin
total
sampl
size
set
sinc
would
provid
trial
power
detect
differ
twosid
signific
level
day
median
time
clinic
improv
two
group
assum
median
time
standardcar
group
day
patient
would
reach
clinic
improv
plan
enrol
patient
trial
occur
quickli
assess
point
trial
underpow
thu
decis
made
continu
enrol
investig
subsequ
anoth
agent
remdesivir
becam
avail
clinic
trial
decid
suspend
enrol
trial
primari
efficaci
analysi
intentiontotreat
basi
includ
patient
undergon
random
time
clinic
improv
assess
patient
reach
day
failur
reach
clinic
improv
death
day
consid
rightcensor
day
rightcensor
occur
event
may
occur
last
time
person
observ
specif
time
event
unknown
time
clinic
improv
portray
kaplanmei
plot
compar
logrank
test
hazard
ratio
confid
interv
calcul
mean
cox
proportionalhazard
model
five
patient
assign
lopinavirritonavir
group
receiv
dose
three
die
within
hour
includ
intentiontotreat
analysi
sinc
reciproc
remov
occur
standardcar
group
modifi
intentiontotreat
analysi
exclud
three
earli
death
also
perform
post
hoc
analys
includ
subgroup
analysi
nation
earli
warn
score
greater
underw
random
day
day
onset
ill
statist
analysi
plan
includ
provis
correct
multipl
test
secondari
outcom
result
report
point
estim
confid
interv
width
confid
interv
adjust
multipl
interv
use
infer
definit
treatment
effect
secondari
outcom
safeti
analys
base
patient
actual
treatment
exposur
statist
analys
conduct
sa
softwar
version
sa
institut
patient
underw
random
patient
assign
receiv
lopinavirritonavir
patient
standard
care
alon
patient
assign
receiv
lopinavirritonavir
receiv
treatment
assign
fig
lopinavirritonavir
group
patient
receiv
dose
lopinavirritonavir
earli
death
within
hour
random
other
attend
physician
refus
prescrib
lopinavirritonavir
random
median
age
patient
year
interquartil
rang
iqr
year
patient
men
tabl
median
interv
time
symptom
onset
random
day
iqr
day
tabl
import
betweengroup
differ
demograph
characterist
baselin
laboratori
test
result
distribut
ordin
scale
score
score
enrol
trial
system
glucocorticoid
administ
patient
lopinavirritonavir
group
standardcar
group
patient
assign
lopinavirritonavir
time
clinic
improv
differ
patient
assign
standard
care
alon
intentiontotreat
popul
median
day
vs
day
hazard
ratio
clinic
improv
confid
interv
ci
p
fig
modifi
intentiontotreat
popul
median
time
clinic
improv
day
lopinavirritonavir
group
compar
day
standardcar
group
hazard
ratio
ci
tabl
fig
supplementari
appendix
intentiontotreat
popul
lopinavirritonavir
treatment
within
day
onset
symptom
found
associ
shorter
time
clinic
improv
hazard
ratio
ci
similar
result
found
regard
later
treatment
lopinavirritonavir
hazard
ratio
ci
fig
signific
differ
observ
time
clinic
improv
assess
score
entri
intentiontotreat
popul
fig
addit
time
clinic
deterior
defin
onecategori
increas
sevencategori
scale
compar
two
group
differ
observ
hazard
ratio
clinic
deterior
ci
fig
mortal
numer
lower
lopinavirritonavir
group
standardcar
group
either
intentiontotreat
popul
vs
differ
percentag
point
ci
modifi
intentionto
treat
popul
vs
differ
percentag
point
ci
tabl
patient
lopinavirritonavir
group
shorter
stay
intens
care
unit
icu
standardcar
group
median
day
vs
day
differ
day
ci
durat
random
hospit
discharg
numer
shorter
median
day
vs
day
differ
day
ci
addit
percentag
patient
clinic
improv
day
higher
lopinavirritonavir
group
standardcar
group
vs
differ
percentag
point
ci
fig
signific
differ
outcom
durat
oxygen
therapi
durat
hospit
time
random
death
total
patient
diagnost
respiratori
tract
sampl
posit
rtpcr
neg
rtpcr
result
throat
swab
taken
consent
mean
baselin
viral
rna
load
throat
swab
taken
consent
slightli
higher
lopinavirritonavir
group
standardcar
group
random
log
copi
per
millilit
vs
tabl
viral
rna
load
time
differ
lopinavirritonavir
recipi
receiv
standard
care
fig
includ
analysi
accord
durat
ill
fig
percentag
patient
detect
viral
rna
similar
lopinavirritonavir
group
standardcar
group
sampl
day
day
vs
day
vs
day
vs
day
vs
day
vs
tabl
total
patient
lopinavirritonavir
group
standard
day
glucocorticoid
therapi
median
iqr
plusminu
valu
mean
ecmo
denot
extracorpor
membran
oxygen
hfnc
highflow
nasal
cannula
oxygen
therapi
nation
earli
warn
score
h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
care
group
report
advers
event
random
day
tabl
gastrointestin
advers
event
includ
nausea
vomit
diarrhea
common
lopinavirritonavir
group
standardcar
group
tabl
percentag
patient
laboratori
abnorm
similar
two
group
tabl
seriou
advers
event
occur
patient
event
lopinavirritonavir
group
event
standardcar
group
tabl
seriou
gastrointestin
advers
event
lopinavirritonavir
group
none
standardcar
group
event
judg
investig
relat
trial
medic
respiratori
failur
acut
kidney
injuri
secondari
infect
common
patient
receiv
standard
care
death
observ
period
judg
site
investig
unrel
intervent
random
trial
found
lopinavirritonavir
treatment
ad
standard
support
care
associ
clinic
improv
mortal
serious
ill
patient
differ
associ
standard
care
alon
howev
modifi
intentiontotreat
analysi
exclud
three
patient
earli
death
betweengroup
differ
median
time
clinic
improv
median
day
vs
day
signific
albeit
modest
note
overal
mortal
trial
substanti
higher
mortal
report
initi
descript
studi
hospit
patient
indic
enrol
sever
ill
popul
patient
popul
heterogen
regard
durat
sever
ill
enrol
post
hoc
subgroup
analysi
differ
mortal
lopinavirritonavir
group
standardcar
group
observ
numer
greater
among
patient
treat
within
day
onset
symptom
among
treat
later
question
whether
earlier
lopinavirritonavir
treatment
could
clinic
benefit
import
one
requir
studi
find
consist
studi
show
patient
viral
pneumonia
progress
second
week
ill
timetotreat
effect
observ
previou
antivir
studi
sar
sever
influenza
addit
found
number
lopinavirritonavir
recipi
seriou
complic
acut
kidney
injuri
secondari
infect
requir
noninvas
invas
mechan
ventil
respiratori
failur
fewer
receiv
treatment
observ
hypothesisgener
requir
addit
studi
determin
whether
lopinavirritonavir
treatment
given
certain
stage
ill
reduc
complic
find
ad
lopinavirritonavir
treatment
reduc
viral
rna
load
durat
viral
rna
detect
compar
standard
support
care
alon
rna
still
detect
patient
lopinavirritonavir
group
end
trial
day
recent
report
show
median
durat
viral
shed
day
patient
sever
ill
could
long
day
neither
studi
current
one
found
evid
lopinavirritonavir
exert
signific
antivir
effect
reason
appar
lack
antivir
effect
uncertain
sampl
method
use
current
trial
like
suboptim
sampl
taken
intermitt
day
frequent
sam
clinic
improv
defin
declin
two
categori
modifi
sevencategori
ordin
scale
clinic
statu
hospit
discharg
icu
denot
intens
care
unit
differ
express
rate
differ
median
differ
hodgeslehmann
estim
confid
interv
hazard
ratio
clinic
improv
estim
cox
proportionalrisk
model
total
includ
patient
die
within
hour
random
receiv
lopinavirritonavir
h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
pling
first
day
could
provid
detail
character
viral
load
kinet
two
group
critic
period
addit
previou
studi
shown
throatswab
specimen
lower
viral
load
nasopharyng
sampl
importantli
unabl
sampl
lower
respiratori
tract
secret
note
depend
cell
type
use
effect
concentr
ec
lopinavir
vitro
sarscov
rang
per
millilit
although
studi
report
lopinavir
inact
higher
concentr
per
millilit
requir
inhibit
merscov
ec
valu
rang
approxim
per
millilit
mean
peak
per
millilit
trough
per
millilit
serum
concentr
lopinavir
adult
approach
concentr
whether
ec
valu
adequ
threshold
whether
unbound
lopinavir
concentr
human
plasma
suffici
inhibit
question
nearli
lopinavirritonavir
recipi
unabl
complet
full
cours
administr
due
primarili
gastrointestin
advers
event
includ
anorexia
nausea
abdomin
discomfort
diarrhea
well
two
seriou
advers
event
acut
gastriti
two
recipi
selflimit
skin
erupt
side
effect
includ
risk
hepat
injuri
pancreat
sever
cutan
erupt
qt
prolong
potenti
multipl
drug
interact
due
inhibit
well
document
drug
combin
sideeffect
profil
observ
current
trial
arous
concern
use
higher
prolong
lopinavirritonavir
dose
regimen
effort
improv
outcom
trial
sever
limit
particular
trial
blind
possibl
knowledg
treatment
assign
might
influenc
clinic
decisionmak
could
affect
ordin
scale
measur
use
continu
follow
patient
evalu
longterm
prognosi
characterist
patient
baselin
gener
balanc
across
two
group
somewhat
higher
throat
viral
load
lopinavirritonavir
group
rais
possibl
group
viral
replic
although
observ
differ
group
frequenc
use
concurr
pharmacolog
intervent
glucocorticoid
might
anoth
confound
addit
approxim
patient
lopinavirritonavir
group
posit
rna
detect
throat
swab
day
day
respect
know
infecti
viru
still
present
sinc
attempt
viru
isol
assess
possibl
emerg
variant
reduc
suscept
lopinavir
final
data
lopinavir
exposur
level
serious
often
critic
ill
patient
conclus
found
lopinavirritonavir
treatment
significantli
acceler
clinic
improv
reduc
mortal
diminish
throat
viral
rna
detect
patient
seriou
earli
data
inform
futur
studi
assess
medic
treatment
infect
whether
combin
lopinavirritonavir
antivir
agent
done
sar
studi
merscov
might
en
bar
indic
confid
interv
result
less
lower
limit
quantif
polymerasechainreact
pcr
assay
greater
limit
qualit
detect
imput
log
copi
per
millilit
result
patient
viralneg
rna
imput
log
copi
per
millilit
among
patient
patient
lopinavirritonavir
group
standardcar
group
virolog
data
use
viral
load
calcul
wherea
rest
patient
undetect
viral
rna
throat
swab
time
advers
event
occur
patient
random
day
shown
patient
one
advers
event
sinc
advers
event
grade
criteria
serum
level
hypersensit
troponin
cardiac
biomark
serum
lipid
proport
patient
valu
wors
baselin
valu
list
proport
increas
hypersensit
troponin
higher
standardcar
group
lopinavirritonavir
group
vs
total
patient
standardcar
group
lopinavirritonavir
group
lipid
level
normal
enrol
abnorm
enrol
death
due
respiratori
failur
ard
indic
acut
respiratori
distress
syndrom
h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
hanc
antivir
effect
improv
clinic
outcom
remain
determin
